Brian Dempster has over 25 years of clinical development experience, gained across a variety of therapeutic areas and geographical regions. He began his career as a CRA before being accepted to Amgen’s Leadership and Management Program. During a decade at Amgen, Brian held program leadership positions in Oncology, Endocrinology and Bone Health in Europe, Canada and the US.
In 2014 Brian joined Vital Therapies (VTL) where he was instrumental in the creation and execution of clinical development strategy, overseeing the entire Phase II and Phase III programs of VTLs combined device and biotherapeutic system for the treatment of liver failure.
Utilizing Fusion eClinical Suite in partnership with Axiom: Before joining Axiom, Brian led the clinical development group at Endologix, which oversaw the global team involved in the pre-approval and post-market clinical development of Endologix’s products, serving patients with a need for abdominal aortic aneurysm sealing and repair.
Brian has a thorough understanding of the clinical development process and has used this to successfully bring products to market. This includes leading teams through several regulatory inspections in relation to submissions, to FDA, MHRA and PMDA. Brian has a particular interest and passion for trial documentation standards, having forged the path for introduction and transition of several eTMF programs.